Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program
There is little information regarding the extent to which difficult to cure patients with advanced liver fibrosis, due to hepatitis C virus genotype-1 (HCV-1) can successfully and safely be treated with triple therapy with telaprevir (TVR), pegylated interferon alpha (P) and ribavirin (R). In the TV...
Saved in:
Published in | Journal of hepatology Vol. 61; no. 5; pp. 976 - 983 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
01.11.2014
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | There is little information regarding the extent to which difficult to cure patients with advanced liver fibrosis, due to hepatitis C virus genotype-1 (HCV-1) can successfully and safely be treated with triple therapy with telaprevir (TVR), pegylated interferon alpha (P) and ribavirin (R). In the TVR early access program HEP3002 we aimed to explore treatment safety and efficacy, and identify predictors of sustained virological response at week 24 (SVR24).
1078 patients with bridging fibrosis (n=552) or cirrhosis (n=526) diagnosed by either liver biopsy or non-invasive markers, with compensated bone marrow (neutrophils >1500/mm(3), Hb >12/13 g/dl) and liver function (Albumin >3.3g/dl, Platelets >90,000/ml) received TVR PR for 12 weeks, followed by a PR tail according to label.
Overall, 614 (57%) achieved SVR24 by intention-to-treat analysis. The SVR24 rate was 68% in 221 treatment naïve patients (62.8% F4), 72% in 356 prior relapsers (64.4% F4), 55% in 139 partial responders (53.2% F4), and 34% in 294 null responders (28.6% F4). The SVR24 rate to response-guided therapy (24 weeks treatment duration if undetectable viremia at weeks 4 and 12) was 84% in 222 naïve/relapser F3 patients. Independent predictors of response were: (A) F3 (odds ratio (OR)=1.51, 95% CI 1.31-2.00, p=0.005), (B) subtype 1b (OR=1.63, 95% CI 1.18-2.24, p=0.0029), (C) alpha-fetoprotein <10 ng/ml (OR=2.50, 95% CI 1.87-3.36, p<0.0001) and (D) any prior response other than null (OR=3.29, 95% CI 2.40-4.52, p<0.0001). SVR24 rose for patients who had more of these predictive factors: 6/32 (19%) for none, 38/139 (27%) for 1, 129/260 (50%) for 2, 202/329 (61%) for 3, and 194/235 (83%) for 4 factors. Grade 2-4 treatment-related adverse events (AE) were experienced by 719 (67%) patients; 169 (16%) discontinued therapy for AE and 7 (0.6%) died during the PR tail.
Naïve and experienced patients with advanced fibrosis or cirrhosis due to HCV-1 who have compensated bone marrow and liver function, can effectively and safely be treated by TVR triple therapy. Baseline predictors of outcome have been identified to optimize pre-treatment counselling. |
---|---|
AbstractList | There is little information regarding the extent to which difficult to cure patients with advanced liver fibrosis, due to hepatitis C virus genotype-1 (HCV-1) can successfully and safely be treated with triple therapy with telaprevir (TVR), pegylated interferon alpha (P) and ribavirin (R). In the TVR early access program HEP3002 we aimed to explore treatment safety and efficacy, and identify predictors of sustained virological response at week 24 (SVR24).
1078 patients with bridging fibrosis (n=552) or cirrhosis (n=526) diagnosed by either liver biopsy or non-invasive markers, with compensated bone marrow (neutrophils >1500/mm(3), Hb >12/13 g/dl) and liver function (Albumin >3.3g/dl, Platelets >90,000/ml) received TVR PR for 12 weeks, followed by a PR tail according to label.
Overall, 614 (57%) achieved SVR24 by intention-to-treat analysis. The SVR24 rate was 68% in 221 treatment naïve patients (62.8% F4), 72% in 356 prior relapsers (64.4% F4), 55% in 139 partial responders (53.2% F4), and 34% in 294 null responders (28.6% F4). The SVR24 rate to response-guided therapy (24 weeks treatment duration if undetectable viremia at weeks 4 and 12) was 84% in 222 naïve/relapser F3 patients. Independent predictors of response were: (A) F3 (odds ratio (OR)=1.51, 95% CI 1.31-2.00, p=0.005), (B) subtype 1b (OR=1.63, 95% CI 1.18-2.24, p=0.0029), (C) alpha-fetoprotein <10 ng/ml (OR=2.50, 95% CI 1.87-3.36, p<0.0001) and (D) any prior response other than null (OR=3.29, 95% CI 2.40-4.52, p<0.0001). SVR24 rose for patients who had more of these predictive factors: 6/32 (19%) for none, 38/139 (27%) for 1, 129/260 (50%) for 2, 202/329 (61%) for 3, and 194/235 (83%) for 4 factors. Grade 2-4 treatment-related adverse events (AE) were experienced by 719 (67%) patients; 169 (16%) discontinued therapy for AE and 7 (0.6%) died during the PR tail.
Naïve and experienced patients with advanced fibrosis or cirrhosis due to HCV-1 who have compensated bone marrow and liver function, can effectively and safely be treated by TVR triple therapy. Baseline predictors of outcome have been identified to optimize pre-treatment counselling. BACKGROUND & AIMSThere is little information regarding the extent to which difficult to cure patients with advanced liver fibrosis, due to hepatitis C virus genotype-1 (HCV-1) can successfully and safely be treated with triple therapy with telaprevir (TVR), pegylated interferon alpha (P) and ribavirin (R). In the TVR early access program HEP3002 we aimed to explore treatment safety and efficacy, and identify predictors of sustained virological response at week 24 (SVR24).METHODS1078 patients with bridging fibrosis (n=552) or cirrhosis (n=526) diagnosed by either liver biopsy or non-invasive markers, with compensated bone marrow (neutrophils >1500/mm(3), Hb >12/13 g/dl) and liver function (Albumin >3.3g/dl, Platelets >90,000/ml) received TVR PR for 12 weeks, followed by a PR tail according to label.RESULTSOverall, 614 (57%) achieved SVR24 by intention-to-treat analysis. The SVR24 rate was 68% in 221 treatment naïve patients (62.8% F4), 72% in 356 prior relapsers (64.4% F4), 55% in 139 partial responders (53.2% F4), and 34% in 294 null responders (28.6% F4). The SVR24 rate to response-guided therapy (24 weeks treatment duration if undetectable viremia at weeks 4 and 12) was 84% in 222 naïve/relapser F3 patients. Independent predictors of response were: (A) F3 (odds ratio (OR)=1.51, 95% CI 1.31-2.00, p=0.005), (B) subtype 1b (OR=1.63, 95% CI 1.18-2.24, p=0.0029), (C) alpha-fetoprotein <10 ng/ml (OR=2.50, 95% CI 1.87-3.36, p<0.0001) and (D) any prior response other than null (OR=3.29, 95% CI 2.40-4.52, p<0.0001). SVR24 rose for patients who had more of these predictive factors: 6/32 (19%) for none, 38/139 (27%) for 1, 129/260 (50%) for 2, 202/329 (61%) for 3, and 194/235 (83%) for 4 factors. Grade 2-4 treatment-related adverse events (AE) were experienced by 719 (67%) patients; 169 (16%) discontinued therapy for AE and 7 (0.6%) died during the PR tail.CONCLUSIONSNaïve and experienced patients with advanced fibrosis or cirrhosis due to HCV-1 who have compensated bone marrow and liver function, can effectively and safely be treated by TVR triple therapy. Baseline predictors of outcome have been identified to optimize pre-treatment counselling. |
Author | Fernández, Inmaculada Abdurakmonov, Djamal Lonjon-Domanec, Isabelle Hill, Andrew Wedemeyer, Heiner Streinu-Cercel, Adrian Colombo, Massimo Urbanek, Petr Abrao Ferreira, Paulo DeMasi, Ralph Moreno, Christophe Iraqi, Wafae Strasser, Simone Verheyen, Anke |
Author_xml | – sequence: 1 givenname: Massimo surname: Colombo fullname: Colombo, Massimo email: massimo.colombo@unimi.it organization: Department of Medicine, Division of Gastroenterology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Milan, Italy. Electronic address: massimo.colombo@unimi.it – sequence: 2 givenname: Simone surname: Strasser fullname: Strasser, Simone organization: AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital and University of Sydney, Sydney, Australia – sequence: 3 givenname: Christophe surname: Moreno fullname: Moreno, Christophe organization: Liver Unit, Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Erasme University Hospital, Université Libre de Bruxelles, Brussels, Belgium – sequence: 4 givenname: Paulo surname: Abrao Ferreira fullname: Abrao Ferreira, Paulo organization: Outpatient Clinic to HIV and Viral Hepatitis Division of Infectious Disease, Federal University of São Paulo, São Paulo, Brazil – sequence: 5 givenname: Petr surname: Urbanek fullname: Urbanek, Petr organization: Department of Internal Medicine, First Medical Faculty, Charles University, and Central Military Hospital Prague, Prague, Czech Republic – sequence: 6 givenname: Inmaculada surname: Fernández fullname: Fernández, Inmaculada organization: Hospital Universitario 12 de Octubre, Sección de Aparato Digestivo, Madrid, Spain – sequence: 7 givenname: Djamal surname: Abdurakmonov fullname: Abdurakmonov, Djamal organization: I.M. Sechenov First Moscow State Medical University, E.M. Tareev Clinic for Nephrology, Internal and Occupational Medicine, Moscow, Russia – sequence: 8 givenname: Adrian surname: Streinu-Cercel fullname: Streinu-Cercel, Adrian organization: Carol Davila University of Medicine and Pharmacy, National Institute for Infectious Diseases "Prof. Dr. Matei Bals", Bucharest, Romania – sequence: 9 givenname: Anke surname: Verheyen fullname: Verheyen, Anke organization: Janssen Pharmaceutica, Beerse, Belgium – sequence: 10 givenname: Wafae surname: Iraqi fullname: Iraqi, Wafae organization: Janssen Pharmaceuticals, Paris, France – sequence: 11 givenname: Ralph surname: DeMasi fullname: DeMasi, Ralph organization: Tibotec Inc., Titusville, NJ, USA – sequence: 12 givenname: Andrew surname: Hill fullname: Hill, Andrew organization: MetaVirology Ltd, London, UK – sequence: 13 givenname: Isabelle surname: Lonjon-Domanec fullname: Lonjon-Domanec, Isabelle organization: Janssen Pharmaceuticals, Paris, France – sequence: 14 givenname: Heiner surname: Wedemeyer fullname: Wedemeyer, Heiner organization: Medizinische Hochschule Hannover, Hannover, Germany |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24946280$$D View this record in MEDLINE/PubMed |
BookMark | eNpNkE1LxDAQhoMo7of-AQ-Sowe3TtI0bb3J4hcseHDvJU1nd7O0aU3SFX-Bf9uAK3gamHnmmeGdkVPbWyTkikHCgMm7fbLf4ZBwYCIBmQBkJ2TKJMACpGATMvN-DwAplOKcTLgoheQFTMn3--iDMhYbejCub_ut0aqlDv3QW4_004QdDdiqwWEEqLGU3UJe0EEFgzb4X0I1B2V1lMQn4iAYT5f3NOwwLgR0NvZ6G73_TEpr9J4Ort861V2Qs41qPV4e65ysnx7Xy5fF6u35dfmwWgyZhAXXSogasoZvciGBFaUSoJtUlBxrKLWq82yTao6cFbzJ64xDwesaVAGp4ArTObn51cazHyP6UHXGa2xbZbEffcUkEzmkhYCIXh_Rse6wqQZnOuW-qr_s0h8QWXO7 |
ContentType | Journal Article |
Copyright | Copyright © 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. |
Copyright_xml | – notice: Copyright © 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. |
DBID | CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.jhep.2014.06.005 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1600-0641 |
EndPage | 983 |
ExternalDocumentID | 24946280 |
Genre | Clinical Trial Multicenter Study Journal Article |
GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29K 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AAXKI AAXUO ABBQC ABFNM ABFRF ABJNI ABMAC ABMZM ABXDB ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE ADMUD ADVLN AEBSH AEFWE AEKER AENEX AEVXI AFCTW AFFNX AFJKZ AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CGR CS3 CUY CVF D-I DU5 EBS ECM EFJIC EIF EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HDZ HMK HMO HVGLF HX~ HZ~ IHE J1W KOM LZ1 M27 M41 MJL MO0 N9A NPM O-L O9- OAUVE OC. ON0 OVD OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSZ T5K TEORI UV1 WUQ X7M YOC Z5R ZGI ~G- 7X8 |
ID | FETCH-LOGICAL-p560-2ca44b05d2f7460189a40cd3492eb09cab75f3c2e2182d7b52082bb0a80342ae3 |
IngestDate | Fri Aug 16 02:13:51 EDT 2024 Sat Sep 28 08:05:11 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Keywords | Cirrhosis Telaprevir Hepatitis C Pegylated interferon |
Language | English |
License | Copyright © 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-p560-2ca44b05d2f7460189a40cd3492eb09cab75f3c2e2182d7b52082bb0a80342ae3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
PMID | 24946280 |
PQID | 1614703840 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_1614703840 pubmed_primary_24946280 |
PublicationCentury | 2000 |
PublicationDate | 2014-Nov 20141101 |
PublicationDateYYYYMMDD | 2014-11-01 |
PublicationDate_xml | – month: 11 year: 2014 text: 2014-Nov |
PublicationDecade | 2010 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands |
PublicationTitle | Journal of hepatology |
PublicationTitleAlternate | J Hepatol |
PublicationYear | 2014 |
SSID | ssj0003094 |
Score | 1.9444624 |
Snippet | There is little information regarding the extent to which difficult to cure patients with advanced liver fibrosis, due to hepatitis C virus genotype-1 (HCV-1)... BACKGROUND & AIMSThere is little information regarding the extent to which difficult to cure patients with advanced liver fibrosis, due to hepatitis C virus... |
SourceID | proquest pubmed |
SourceType | Aggregation Database Index Database |
StartPage | 976 |
SubjectTerms | Adult Aged Antiviral Agents - administration & dosage Antiviral Agents - therapeutic use Drug Therapy, Combination Female Hepacivirus - classification Hepacivirus - drug effects Hepacivirus - genetics Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - virology Humans Interferon-alpha - administration & dosage Liver Cirrhosis - drug therapy Liver Cirrhosis - virology Male Middle Aged Oligopeptides - administration & dosage Oligopeptides - therapeutic use Polyethylene Glycols - administration & dosage Recombinant Proteins - administration & dosage Ribavirin - administration & dosage Treatment Outcome Young Adult |
Title | Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program |
URI | https://www.ncbi.nlm.nih.gov/pubmed/24946280 https://search.proquest.com/docview/1614703840 |
Volume | 61 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEF6cFEIuJW3zapOwhd5SGT12JTm3IBJCwb3UhdzMrjQmDrFkFPnSQ675G_2pnX1JcltD2ouQd80aaz7Nzs5-3ywhn1guZSAg8JICwGMxRJ7kifR0-bOZiFnKld55_DW--c6-3PLbweBnj7W0auQw__FXXcn_WBXb0K5KJfsPlm0HxQa8R_viFS2M1xfZ-JtRP2HMqNRqzovVhvYKNscKD2KpubwqtYF-K8Pp2pVTddo2RwS4A9XRzB_PM0f4mK-lDHujCX3UoiN4bQhy9YBrmfsMPy1kZXRC-EIuqjbJ09RCkQN0Qhbbuw3_cVVDWa3XQuj2rWpRnV9DXcNcn5mkyY5VP5sRMCvr05OR8cCxkrrHphqWc9GmXruFIu_525E5POaPecCkJO6H9_g3FX-P6SKtWuDd9ICxXGhk4BJUSXT9bk5smYqua4u8CpMRV6TR4VNHIopwdWylWIY1-PsPqmLTdojNaxgdy0z2yGtrH3ppEPWGDKB8S3bGlmbxjjy3wKI9YFEHLKpAQzso0HlJg88IK-pgZb7hYEVbWNHsgiKo6Bqo-iMZUFELqn0yub6aZDeePbHDW2Lk7IW5YEz6vAhnCcOVfjoSzM8LVQATpD_KhUz4LMpDUMcGFInkIQagUvoiVYUoBUQHZLtEdB0ROisSJkGEBQtylkIqYx5BXAQ-hCnkUXpMPrqHOUWHqHa5RAnV6nGKSxiG01jK_GNyaJ7ydGkqt0ydKd5v7PlAdjtYnpDtpl7BKYadjTzTlv8FQsaJ5g |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Elsevier |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Sustained+virological+response+with+telaprevir+in+1%2C078+patients+with+advanced+hepatitis+C%3A+the+international+telaprevir+access+program&rft.jtitle=Journal+of+hepatology&rft.au=Colombo%2C+Massimo&rft.au=Strasser%2C+Simone&rft.au=Moreno%2C+Christophe&rft.au=Abrao+Ferreira%2C+Paulo&rft.date=2014-11-01&rft.eissn=1600-0641&rft.volume=61&rft.issue=5&rft.spage=976&rft_id=info:doi/10.1016%2Fj.jhep.2014.06.005&rft_id=info%3Apmid%2F24946280&rft.externalDocID=24946280 |